Impact of the use of Kampo medicine in patients with esophageal cancer during chemotherapy:a clinical trial for oral hygiene and oral condition

DOI Web Site PubMed 被引用文献1件 参考文献1件
  • Moriyama Satomi
    Department of Hygiene and Oral Health Science, Tokushima University Graduate School of Biomedical Sciences
  • Hinode Daisuke
    Department of Hygiene and Oral Health Science, Tokushima University Graduate School of Biomedical Sciences
  • Yoshioka Masami
    Department of Oral Health Science and Social Welfare, Tokushima University Graduate School of Biomedical Sciences
  • Sogawa Yuka
    Department of Hygiene and Oral Health Science, Tokushima University Graduate School of Biomedical Sciences
  • Nishino Takeshi
    Department of Thoracic Endocrine Surgery and Oncology, Tokushima University Graduate School of Biomedical Sciences
  • Tangoku Akira
    Department of Thoracic Endocrine Surgery and Oncology, Tokushima University Graduate School of Biomedical Sciences
  • Grenier Daniel
    Groupe de Recherche en Ecologie Buccale, Faculte de Medecine Dentaire, Universite Laval

この論文をさがす

説明

<p>Objective:The aim of this study was to investigate the impact of the use of two Kampo medicines on oral mucositis, tongue coating bacteria, and gingiva condition in patients with esophageal cancer undergoing chemotherapy. Methods:Twenty‐three esophageal cancer patients who receive chemotherapy at Tokushima University Hospital, were included. The participants, who received professional oral healthcare, were randomly divided into three groups:7 subjects received Daiokanzoto sherbets, 7 subjects received Hangeshashinto sherbets, and 9 subjects received nothing (control). The numbers of total bacteria and specific periodontopathogenic bacteria in tongue coating were determined in addition to clinical parameters. Results:No difference on the onset of oral mucositis was found among the three groups. However, tongue coating index, gingival index (GI), plaque index, the number of total bacteria, Fusobacterium nucleatum and Campylobacter rectus were decreased during chemotherapy. More specifically, GI as well as the number of F. nucleatum and C. rectus were decreased significantly in the Daiokanzoto group when compared to the control group (psize 8 < 0.05). No such differences were observed for the group receiving Hangeshashinto. Conclusion:This clinical trial showed that Daiokanzoto might be effective in attenuating gingival inflammation and reducing the levels of periodontopathogenic bacteria in patients with esophageal cancer. J. Med. Invest. 65:184‐190, August, 2018</p>

収録刊行物

被引用文献 (1)*注記

もっと見る

参考文献 (1)*注記

もっと見る

関連プロジェクト

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ